Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands

ChemMedChem. 2022 May 4;17(9):e202200058. doi: 10.1002/cmdc.202200058. Epub 2022 Mar 4.

Abstract

The design, synthesis, X-ray structural, and biological evaluation of a series of highly potent HIV-1 protease inhibitors are reported herein. These inhibitors incorporate novel cyclohexane-fused tricyclic bis-tetrahydrofuran as P2 ligands in combination with a variety of P1 and P2' ligands. The inhibitor with a difluoromethylphenyl P1 ligand and a cyclopropylaminobenzothiazole P2' ligand exhibited the most potent antiviral activity. Also, it maintained potent antiviral activity against a panel of highly multidrug-resistant HIV-1 variants. The corresponding inhibitor with an enantiomeric ligand was significantly less potent in these antiviral assays. The new P2 ligands were synthesized in optically active form using enzymatic desymmetrization of meso-diols as the key step. To obtain molecular insight, two high-resolution X-ray structures of inhibitor-bound HIV-1 protease were determined and structural analyses have been highlighted.

Keywords: HIV-1 protease; antiviral agents; backbone binding; inhibitors; multidrug-resistance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Intramural

MeSH terms

  • Crystallography, X-Ray
  • Drug Design
  • HIV Protease / metabolism
  • HIV Protease Inhibitors* / chemistry
  • HIV-1* / metabolism
  • Ligands
  • Structure-Activity Relationship
  • X-Rays

Substances

  • HIV Protease Inhibitors
  • Ligands
  • HIV Protease
  • p16 protease, Human immunodeficiency virus 1